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Key points
 A correlationwas found between in vivo umbilical arteryDoppler velocimetry and resistance to
fetal-side flow in the human ex vivo dually perfused placenta, highlighting that the fetoplacental
vascular bed is a key site of resistance to umbilico-placental flow in pregnancy.
 We discovered high resistance and poor flow-mediated vasodilatory responses in placentas
from pregnancies associated with fetal growth restriction (FGR).
 Endothelial cells isolated from the FGR placentas and grown in static and flow culture showed
a dysregulated phenotype, with biochemical signalling demonstrating a failed compensatory
response to high blood-flow resistance.
Abstract Increased vascular resistance and reduced fetoplacental blood flow are putative
aetiologies in the pathogenesis of fetal growth restriction (FGR); however, the regulating sites
and mechanisms remain unclear. We hypothesised that placental vessels dictate fetoplacental
resistance and in FGR exhibit endothelial dysfunction and reduced flow-mediated vasodilatation
(FMVD). Resistance was measured in normal pregnancies (n = 10) and FGR (n = 10) both in
vivo by umbilical artery Doppler velocimetry and ex vivo by dual placental perfusion. Ex vivo
FMVD is the reduction in fetal-side inflow hydrostatic pressure (FIHP) following increased flow
rate. Results demonstrated a significant correlation between vascular resistance measured in vivo
and ex vivo in normal pregnancy, but not in FGR. In perfused FGR placentas, vascular resistance
was significantly elevated compared to normal placentas (58± 7.7mmHg and 36.8± 4.5mmHg,
respectively; 8mlmin−1;means± SEM;P< 0.0001) and FMVDwas severely reduced (3.9± 1.3%
and 9.1 ± 1.2%, respectively). In normal pregnancies only, the highest level of ex vivo FMVD
was associated with the lowest in vivo resistance. Inhibition of NO synthesis during perfusion
(100 μM L-NNA) moderately elevated FIHP in the normal group, but substantially in the FGR
group. Human placenta artery endothelial cells from FGR groups exhibited increased shear
stress-induced NO generation, iNOS expression and eNOS expression compared with normal
groups. In conclusion, fetoplacental resistance is determined by placental vessels, and is increased
in FGR. The latter also exhibit reduced FMVD, but with a partial compensatory increased NO
generation capacity. The data support our hypothesis, which highlights the importance of FMVD
regulation in normal and dysfunctional placentation.
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Introduction
Fetal growth restriction (FGR) is a serious pregnancy
complication, which affects 3–8% of pregnancies (Alberry
& Soothill, 2007) and is associated with a significant
increase in perinatal morbidity, mortality and stillbirth
(Yanney & Marlow, 2004; Figueroa-Diesel et al. 2007).
Correlations between low birth weight and increased risk
of cardiovascular disease in adulthood have also been
well documented (Barker et al. 1989; Barker et al. 1995;
Demicheva & Crispi, 2013), with growing evidence that
programming during prenatal life can predispose to adult
cardiovascular andother diseases (Palinski&Napoli, 2008;
Thornburg et al. 2010). Currently there are no proven
therapies available to prevent or treat FGR; the only option
available is delivery, often preterm, which is associated
with its own risks (Lawn et al. 2005).
Abnormal placentation, with reduced fetoplacental
blood flow, is a major cause of FGR (Chaddha et al.
2004; Sibley et al. 2005; Kiserud et al. 2006). In
healthy pregnancies, placental vascular resistance changes
dramatically in the third trimester resulting in a high
flow, low resistance circulation, achieved through vascular
adaptations including angiogenesis and vasodilatation
(Sala et al. 1995; Chaddha et al. 2004). In severe cases of
FGR, these adaptations fail to occur properly (Baschat,
2004) and vascular resistance remains high, observed
clinically as increased pulsatility and resistance indices
(PI and RI) in umbilical artery Doppler assessment
(Acharya et al. 2005). The severity of fetal compromise
in pregnancies affected by FGR is reflected by the
degree of abnormality of the Doppler waveform, with
absent or reversed flow at the end of diastole (Ghosh
& Gudmundsson, 2009; Vergani et al. 2010). In these
cases the flow in the umbilical artery is often inter-
mittent, with a rapid progression of demise, suggesting
that increased vascular resistance in FGR cannot solely
be attributed to the structural constraints of an altered
vascular architecture; dysregulation of vascular tone is also
likely to play an important role (Turan et al. 2008).
Vascular tone in the fetoplacental circulation is
principally regulated by endocrine or mechanical stimuli
since it lacks autonomic innervation (Marzioni et al.2004).
Vasodilators responsible for relaxing smooth muscle and
maintaining low vascular resistance include nitric oxide
(NO), prostacyclin (PGI2), and endothelial derived hyper-
polarising factor (EDHF) (Poston, 1997) with possible
roles for carbon monoxide (CO) (Lyall et al. 2000;
Bainbridge et al. 2002) and hydrogen sulphide (H2S2)
(Holwerda et al. 2012; Cindrova-Davies et al. 2013; Wang
et al. 2013). NO is the most studied of the vasodilators in
the fetoplacental circulation, and evidence suggests that
it plays a crucial role in the pregnancy induced vascular
adaptations involved inmaintaining low resistance (Baylis
et al. 1992; Myatt, 1992; Magness et al. 1997; Sladek et al.
1997; Kulandavelu et al. 2012).
In many vascular beds one of the most potent
stimulators of NO synthesis and vasodilatation is shear
stress, the frictional force between flowing blood and
the endothelium, calculated from the flow rate, visco-
sity of blood and radius of the vessel (Sprague et al.
2010). In the placenta, it has been shown that inhibition
of NO during placental perfusion significantly increases
pressure in the fetal circulation when shear stress is
elevated through increased flow rate or increased fluid
viscosity (Wieczorek et al. 1995). Shear stress has also been
shown to increase eNOSexpression andactivation inovine
fetoplacental endothelial cells (Li et al. 2004). Endothelial
dysfunction and an inability to respond appropriately to
shear stress and increased blood flow would therefore
result in increased vascular resistance similar to that seen
in the placenta of pregnancies affected by severe FGR.
In the current study we tested the hypotheses that
placental vessels dictate fetoplacental resistance and that
in FGR these vessels exhibit endothelial dysfunction and
reduced flow-mediated vasodilatation (FMVD).
Using human ex vivo dual placental perfusion we
measured vascular resistance and FMVD in the feto-
placental vasculature of normal and FGR pregnancies,
and correlated these with resistance data obtained in vivo
via umbilical artery Doppler velocimetry. We also directly
investigated endothelial responses to shear stress using
human placental chorionic plate artery endothelial cells
(HPAECs) from normal and FGR pregnancy in an in vitro
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laminarflowsystem. Inaddition the roleofNOinplacental
endothelial responses to shear stress in normal and FGR
pregnancy was investigated.
Methods
Ethical approval
Procedures were followed in accordance with institutional
guidelines and conformed to the standards set by the
latest revision of the Declaration of Helsinki. All tissue
was acquired with written consent from fully informed
women attending StMary’s Hospital,Manchester for their
antenatal care. Tissues were collected following informed
consent, under ethical approval by the North West
Haydock Park Research Ethics Committee (08/H1010/05)
and the University of Manchester Ethics Committee.
Human placentas from healthy control pregnancies
and FGR pregnancies were collected within 30 min
of delivery by Caesarean section or vaginal delivery.
Volunteer demographics are given in Table 1. In this
study, idiopathic FGR was defined as an individualised
birthweight centile (IBC) at or below thefifth centile, using
an algorithm (GROW) accounting for maternal height,
weight at booking, parity, gestational age, ethnicity, fetal
sex and birth weight (Gardosi, 2006). Only singleton pre-
gnancies were recruited and patients were excluded if they
had pre-existing hypertension, pre-eclampsia, diabetes,
renal disease, or a body mass index <18.5 or >30.
Doppler ultrasound measurements of the umbilical
artery
Doppler velocimetrymeasurementsof theumbilical artery
free loop were obtained within 1 week of delivery using
a Voluson E6 with RA4B 3D 4–8 MHz curvilinear probe
(GE Healthcare, UK). The PI and RI were then calculated.
PI = (S – D)/A and RI = (S – D)/S, where S is the systolic
peak, D is the end diastolic flow and A is the temporal
average frequency.
Ex vivo dual perfusion of human placental cotyledons
The fetal sex of placentas used in perfusions is given
in Table 1. Perfusion of one or more grouped placental
cotyledons was established as previously described
(Brownbill & Sibley, 2006). Briefly, experiments were
performed in a humidified cabinet at 37°C. The perfusate
was modified Earle’s bicarbonate buffer (EBB; 117 mM
NaCl, 10.7 mM KCl, 5.6 mM D-glucose, 3.6 mM CaCl2,
1.8mMNaH2PO4, 13.6mMNaHCO3, 0.04mM L-arginine,
0.8 mM MgSO4, 3.5% (w/v) dextran, 0.1% (w/v) bovine
serum albumin, 5000 IU l–1 heparin sodium) equilibrated
with 95% O2–5% CO2 to pH 7.4 and warmed to 37°C.
The fetal circulation was initially perfused at a standard
circulation flow rate of 6 ml min−1. Fetal-side inflow
hydrostatic pressure (FIHP) was recorded continuously
throughout the experiments as a measure of fetoplacental
vascular resistance and vasodilatation in response to
altered flow rates (maternal and fetal hydrostatic pressure
transducers: Medex, Digitimer, Welwyn Garden City, UK;
Nanologger and associated software, Gaeltec, Isle of Skye,
Scotland). FIHPwasmeasured as an indication of vascular
resistance at steady state following incremental increases
in fetal-side inflow rate. The maternal circulation was
perfused at a constant flow rate of 14 ml min−1 via
perfusion manifold (Harvard Apparatus, Model MPP-5
Perfusion Manifold, 5 Inputs). n = 10 lobules from
normal pregnancies and n = 10 FGR pregnancies were
studied. Two FGR cases had absent end-diastolic flow in
the umbilical artery, preventing their inclusion in some
data sets.
Upon the establishment of dual-sided perfusion in
open-circuit, placentas were left to equilibrate for 20 min.
The fetal-inflow rate was then ramped rapidly between
2 ml min−1 and 12 ml min−1 until the pressure at
12mlmin−1 remained constant to ensure that all available
vessels within the cotyledon were open. For experimental
observations, fetal-inflowratewas incrementally increased
from 2 ml min−1 through to 12 ml min−1 (2, 4, 6, 8,
10 and 12 ml min−1), with 7 min intervals at each flow
rate to allow a steady state FIHP to be achieved. The
rampingprocesswasperformed twice andall experimental
values were taken during a second ramping stage to
ensure adequate perfusion efficiency and accuracy of the
response. In experiments where NO synthase was blocked
Nω-nitro-L-arginine (L-NNA; 100 μM) or vehicle control
(0.025% (v/v) HCl) was added to the EBB for 40 min
at a standard fetal-inflow rate (6 ml min−1) and then
maintained prior to repeating the two sets of fetal-side
flow ramps. Vascular resistance was taken as the mean
steady stateFIHP,measuredbetween6and7min following
alteration of flow. FMVD was measured as the percentage
reduction in FIHP from peak FIHP following alteration of
flow, to themean steady state FIHP,measured as described
above.
Isolation and culture of HPAECs
HPAECs were isolated from chorionic placental vessels of
normal and FGR pregnancies using a method previously
described (Lang et al. 2008). The sex of the cell lines is
given in Table 1. Cells were maintained in microvascular
endothelial growth medium (EGM-MV; Lonza, UK)
supplemented with 10 ng ml−1 fibroblast growth factor 2
(FGF-2; R&D Systems, UK) and 6.7 ngml−1 vascular end-
othelial growth factor-165 (VEGF-165; Peprotech, UK) at
37°C in a humidified atmosphere with 5% CO2. Medium
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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Table 1. Clinical and outcome characteristics
Perfusion study Normal (n = 10) FGR (n = 10) P
Maternal age (years) 29.5 [25.75–33] 29 [22.75–34.75] 0.91
BMI 22.9 [22.4–27.5] 25 [22.75–27.50] 0.649
Parity 1 [0–1.25] 1 [0.75–2.25] 0.362
Gestation (weeks) 39.2 [38.9–40.6] 37.5 [35.63–39.18] < 0.05∗
Delivery (V/CS)† 2/8 4/6 N.A
PI‡ 0.88 [0.80–0.93] 1.09 [0.908–1.783] < 0.05∗
RI‡ 0.565 [0.528–0.603] 0.670 [0.612–0.800] < 0.005∗∗∗
Birth weight (g) 3517 [3359–3704] 2189 [1518–2483] < 0.001∗∗∗
IBR (centile) 61 [22–84.3] 1 [0–2.5] < 0.001∗∗∗
Offspring sex# 6M, 4F 4M, 6F N.A
Placenta disc weight (g) 499 [438–642] 279 [225–372] < 0.001∗∗∗
Perfused lobule weight (g) 49.75 [42–76] 43.75 [24–72] 0.623
HPAEC study Normal (n = 7) FGR (n = 7) P
Maternal age (years) 26 [23–29] 26 [23–33] 0.364
BMI 25 [23–26] 23 [21–25] 0.174
Parity 1 [0–2] 1[0–2] 0.947
Gestation (weeks) 39 [38.1–39.0] 38 [36–39.4] 0.653
Delivery (V/CS)† 0/7 6/1 N.A.
Birth weight (g) 3816 [3560–3860] 2440 [1980–2778] < 0.001∗∗∗
IBR (centile) 83 [75–88] 3 [1–5] < 0.005∗∗
Offspring sex# 3M, 4F 4M, 3F N.A.
Placenta disc weight (g) 588 [532–660] 432 [294–455] < 0.005∗∗
Values are shown as median [interquartile range]; statistical analysis was performed using a Mann–Whitney U test. BMI, body mass
index; IBR, individualised birth weight ratio. †Vaginal (V)/Caesarean section (CS). ‡Pulsitility index (PI) and resistance index (RI) values
represent n = 8 for the FGR group since there was absent end diastolic flow in two of the pregnancies. #Male (M), female (F).
was changed every 2–3 days and cells were passaged when
they achieved 70% confluency.
A human placenta was obtained within 30 min
of delivery, the amnion removed and two to four
chorionic plate arteries dissected off the chorionic plate
(intermediate diameter: 1–2 mm; minimum length:
3 cm without side branching). Each artery was placed
into a 50 ml capped tube containing 20 ml sterile
Hanks’ balanced salt solution (HBSS) (with calcium and
magnesium, Invitrogen, UK), agitated to release excess
blood and transferred to a new tubes with fresh 20 ml
HBSS.
In turn, each artery was catheterised and the end-
othelial cells digested and flushed out of the vessel within
a biological safety cabinet: the plastic sheath of an 18G
catheter (Venflon; NuCare, UK) was cut with sterile
scissors to a bevelled form. The washed artery was placed
on a sterile chromatography glass plate in the biological
safety cabinet and cannulated. The metal needle was
withdrawn and a 15 cm length of fine fishing line was used
to tie the artery onto the cannula. Twenty millilitres of
collagenase/dispase enzyme solution was drawn up into
a 20 ml syringe. The syringe was Luer-locked attached
to the catheter, the assembly was held vertically with the
vessel dangling, and the enzyme solution (0.1 U ml−1
collagenase, 0.8 U ml−1 dispase, Roche Diagnostics, cat
no. 11 097 113 01; prepared in Ca2+- and Mg2+-free
HBSS, Gibco, supplied by Invitrogen, UK) was slowly
eluted through the vessel lumen across a 7 min period,
with the first three bloody drops going to waste. The cell
digest solution emanating from the distal cut-end of the
vessel was caught into a 5 ml quench solution of 100%
(v/v) heat-inactivated fetal bovine serum (FBS; Gibco
from Invitrogen, UK).
The cell digest and calf serum were mixed thoroughly
and centrifuged at 200 g for 10 min at ambient room
temperature. The cell pellet was not visible due to a
low cell count, so the supernatant was aspirated to
waste leaving 200 μl, which was re-suspended into
3 ml of supplemented microvascular endothelial basal
growth medium (EBM-MV bullet kit, Lonza, Belgium,
supplied supplementary bullets: gentamycin sulphate/
amphotericin-B, bovine brain extract, hydrocortisone
rhEGF, FBS; the prepared medium was additionally
supplemented with 88 pmol l–1 rhVEGF-A165, Peprotec,
UK and 590 pmol l–1 rhFGF-2, R&D Systems, UK). The
resuspension from each vessel was added to one well
of the coated 24-well plate (attachment factor protein
from Gibco, supplied by Invitrogen, UK) and incubated
(37°C, 5% CO2, ambient O2). After 1 h of incubation,
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the medium was replaced with 1ml fresh EBM-MV and
incubated for 1–2 weeks, changing the medium every day
for the first three days and every three days thereafter.
HPAECs had a classic, cobblestone morphology when
confluent, preceded by an elongated form, with pseudo-
podia appearing to make contact between cells when
sparse. At between 2 and 4 weeks of culture, sufficient cells
(ca 2000) were present as colonies growing from the well
periphery, which were then trypsinised (trypsin-EDTA;
Lonza, Belgium) and passaged into a well of a six-well
plate (uncoated here on in). Subsequent passaging
occurred at 70–80% confluency. Trypsinisation was
preceded with a Ca2+- and Mg2+-free HBSS wash. The
second passage was into 1 × T25 flask, the third into 1 ×
T75 flask, the fourth into 4 × T75 flasks and the fifth into
4–6 × T175 flasks. From this point, cells were available
for experimental use, characterisation and cryogenic
storage (storage medium: supplemented EGM-MV +
10% dimethyl sulphoxide; Sigma-Aldrich, cell culture
grade).
Characterisation of HPAECs
HPAECs were seeded (5 × 104−1 × 105 cells) onto sterile
12 mm glass coverslips in a 24-well plate. At confluency
theywerefixed in100%coldmethanol (30min) and stored
under sterile PBS for use in immunohistochemistry. They
were stained for endothelium-specific markers: mouse
monoclonal anti-human CD31 (CD31; Dako, cat no.
M0823, 1 in 50), VEGF receptor 2 (VEGFR2; anti-VEGF
R2/KDRfluorescein conjugatedmouse IgG;R&DSystems,
cat no. FAB357F, 1 in 10), von Willebrand factor (poly-
clonal rabbit anti-human, Dako, cat no. A0082, stock
concentration 3.1 mg ml−1, 1 in 250), and Ulex europaeus
agglutinin 1 lectin (direct fluorescent conjugate; Vector
Laboratories, 1 in 25). Smooth muscle α-actin was used
as a negative control (mouse monoclonal anti-human;
Dako, cat no. M085, 1 in 100). Vectashield mounting
medium was used with 4’,6-diamidino-2-phenylindole
(DAPI). Secondary antibodies, fluorescently labelled with
fluorescein isothiocyanate, were used accordingly: (i)
polyclonal rabbit anti-mouse (Dako, cat no. F0232, 1 in
50); and (ii) polyclonal swine anti-rabbit IgG (Dako, cat
no. F0205, 1 in 50).
Shear stress studies on HPAECs
Details on the preparation of materials and loading of
microslides (0.4 mm Luer, T/C treated; Thistle Scientific,
UK) can be found at: http://ibidi.com/xtproducts/
en/ibidi-Labware/Flow-Chambers/m-Slide-I-Luer-Family.
Unidirectional laminar shear-stress experiments on
HPAECs were performed using Ibidi fluidic units (Thistle
Scientific, UK), on HPAECs between passages 5 and 8
to assess the role of the NO synthase systems between
normal and FGR groups. Cells were plated onto Ibidi
μ-slides (0.4 Luer T/C treated; Thistle Scientific, UK) at
a density of 1×105 cells per slide and cultured overnight
to achieve a confluent monolayer. Medium was replaced
and four μ-slides were attached in series to a single fluidic
unit. Cell culture medium flowing across the attached
cells was driven by the fluidic unit coupled to an air
pump, delivering software-generated flow rates equating
to a pre-set shear stress for 48 h. Several fluidic units were
used in parallel for different treatments, or at different
shear-stresses (5, 10 or 20 dyn cm–2; n = 6 for each of
the normal and FGR groups; n = 5 for each group in
the presence and absence of L-NNA, paired analysis).
In a modification to the system, for the addition of
L-NNA or vehicle and the removal of samples from the
reservoirs, a sterile silicone injection port was built into
the Ibidi fluidic unit (Thistle Scientific, UK) between
one of the syringe barrel reservoirs and the perfusion
set. Injections and withdrawals (25G needle and 1 ml
syringe) were limited to 0.5 ml (isotonic diluent) and
done whilst the associated barrel was in filling mode, so
as not to influence the shear rate across the cells during
the procedure. At the end of the shear stress run, cell
lysates were recovered from Ibidi slides by placing the
slides directly onto ice and eluting with 125 μl ice-cold
radio-immunoprecipitation assay (RIPA) buffer. Lysates
were merged from all four slides and flow-conditioned
medium was collected from the perfusion sets and stored
at –80°C. Lysate protein levels were determined using a
micro-BCA protein detection kit (Pierce, UK). Culture
conditioned medium was sampled via the perfusion set
ports at 0, 1, 4, 24 and 48 h and stored at –80°C for
the later determination of levels of nitrite, the stable
breakdown product of NO (Greiss reaction assay kit; Life
Technologies, UK).
Samples of medium were taken via a needle port at
1, 4, 24 and 48 h for nitrite analysis, using the Griess
reaction following the manufacturer’s instructions (Life
Technologies, UK). Immediately on cessation of flow,
cell lysates were recovered at the end of the shear stress
experiments by eluting theμ-slide chambers with ice-cold
RIPAbuffer containing protease inhibitor cocktail. Protein
concentration was established using a micro-BCA kit
(Pierce, UK) and lysates stored at –80°C prior to Western
blotting and phosphokinase array assay.
Western blotting
eNOS, phosphoserine1177-eNOS (P-Ser1177-eNOS) and
iNOS expression were compared in HPAECs between
groups in static culture (n = 3, 7 and 7 from normal
pregnancy and n = 4, 7 and 7 from FGR pregnancy;
cells harvested at T = 48 h). In a separate study using
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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normal HPACEs, eNOS and P-Ser1177-eNOS expression
were analysed between static and shear stress culture
(20 dyn cm–2; n = 7 per environment; cells harvested at
T = 48 hours). Proteins were separated using SDS–PAGE
(7.5% resolving gel) and transferred to Immobilon-P
polyvinylidene difluoride membranes (Millipore, UK).
Membranes were probed with rabbit polyclonal
anti-eNOS (1:1000), anti-phospho-eNOS (Ser1177)
(1:1000), anti-β-actin (1:2000) (all from New England
Biolabs, UK) or anti-iNOS (1:200) (Abcam, UK) anti-
bodies overnight at 4°C. The following day membranes
were washed (×3) in Tris-buffered saline–Tween
(50 mmol l–1 Tris-HCl, 150 mmol l–1 NaCl, 0.02%
(v/v) Tween, pH 7.4), and incubated with horseradish
peroxidase-conjugated secondary antibody (Dako, UK)
for 1 h at room temperature. Proteins were detected used
enhanced chemiluminescence (Fisher Scientific, UK) and
visualised using X-ray film (Kodak, Biomax MR-1).
Phosphokinase array
A proteome profiler human phosphokinase array (R&D
Systems, Inc., UK) was performed on pooled normal and
pooledFGRHPAEC lysates (n=4 cell lines for eachgroup)
following the manufacturer’s instructions.
Statistical analysis
Data are presented as means ± SEM. Statistical analysis
was performed using a two-way ANOVA and Bonferroni
post hoc test. Correlations were performed using the
Pearson correlation coefficient and comparisons between
twogroupswereperformedusingStudent’s t test for paired
or unpaired data, or Sidak’s multiple comparison test.
Statistical significance was taken as P< 0.05. Data analysis
was performed using GraphPad Prism version 5.
Results
Fetal vascular resistance measured in vivo
by umbilical artery Doppler velocimetry reflects
vascular resistance in the fetoplacental circulation
Correlation of ex vivo FIHP measured during perfusion
with in vivo umbilical artery Doppler RI and PI
measurements revealed a significant positive correlation
in healthy pregnancy. FIHP at an inflow rate of 6mlmin−1
(Fig. 1A) and 12 ml min−1 (data not shown) correlated
with PI (r2 = 0.649, P < 0.01, and 0.515, P < 0.05
respectively). Correlations between FIHP and RI were
even stronger with an r2 of 0.709 (P < 0.01) at a flow
rate of 6 ml min−1 (Fig. 1B) and 0.547 (P < 0.05) at
12 ml min−1 (data not shown). In the FGR group there
was no overall correlation; in vivo velocimetry values were
spread over a much wider range and the placentas with
the highest Doppler indices did not always display the
highest resistance values during perfusion at 6 ml min−1
(Fig. 1C and D). The clinical characteristics of the patient
study groups used in perfusion experiments are provided
in Table 1.
Ex vivo fetoplacental vascular resistance is higher
in FGR placentas compared to normal placentas
As expected, vascular resistance increased with increasing
flowrates in both thenormal and theFGRperfused lobules
(Fig. 2A). However, in FGR placentas steady state FIHP
was higher at each flow rate than in placentas fromnormal
pregnancies, an effect particularly evident at higher inflow
rates (Fig. 2B; e.g. 72.3 ± 29.3 and 42.4 ± 19.0 mmHg,
mean ± SD, respectively, at 12 ml min−1; 2-way ANOVA
across 2–12 ml min−1 flow range, group effect: P < 0.05;
Bonferroni post hoc test at inflow rates of 8, 10 and
12mlmin−1:P<0.05,P<0.01 andP<0.01, respectively).
FMVD in the placental vasculature is markedly
reduced in FGR compared to normal pregnancy
Examining the data collected during the FIHP protocol
noted above, we determined that placentas from the
normal group demonstrated noticeable FMVD following
each incremental increase in flow rate, with the largest
responses occurring at 6 ml min−1 and 8 ml min−1
(9.06 ± 4.30% and 9.07 ± 3.92% reduction in FIHP,
respectively; Fig. 2C). In contrast, FMVDinplacentas from
FGR pregnancies was often absent or markedly reduced
compared to controls (3.7 ± 5.30% at 6 ml min−1 and
3.95 ± 4.15% at 8 ml min−1, P < 0.01, mean ± SD;
Fig. 2C; 2-way ANOVA group effect across the full flow
range: P < 0.0001; Bonferroni post hoc test at 6, 8 and
12mlmin−1:P< 0.01,P< 0.01 andP< 0.05, respectively)
suggesting that placental vessels in FGR exhibit impaired
FMVD.
In normal pregnancy, the extent of this FMVD response
negatively correlated with the umbilical artery Doppler
measurements when flow was elevated to 6 ml min−1
(Fig. 3A and B) and 12 ml min−1 (data not shown). Both
PI and RI significantly correlated with FMVD (r2 = 0.526,
P< 0.05 and r2 = 0.619, P< 0.01, respectively) indicating
that reduced FMVD is associated with increased vascular
resistance in the placenta. In the FGR group, FMVD at an
inflow rate of 6 ml min−1 was completely absent in four
of the five placentas which had poor Dopplers, and one
which had a normal Doppler (Fig. 3C andD); results were
similar at 12 ml min−1 (data not shown).
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NO has a role in regulating vascular resistance
and flow-mediated vasodilatation in the placental
vasculature
A second phase of perfusion in the same preparations
in the presence of the NO synthase inhibitor L-NNA
(100 μM) resulted in a small elevation in FIHP in healthy
pregnancies, which was significant at higher flow rates
(Fig. 4A; 2-wayANOVA:P<0.001). In contrast, inhibition
of NO synthesis in FGR placentas resulted in a marked
elevation in FIHP, which was significant at flow rates
at and above 8 ml min−1 (Fig. 4B; 2-way ANOVA:
P< 0.0001), indicating a greater role for theNO signalling
axis in lowering vascular resistance in FGR versus normal
placentas.
In the normal placenta perfusions, FMVD was signi-
ficantly reduced when NO release was inhibited with
L-NNA (100 μM) indicating a pivotal role for NO in
facilitating the FMVD vascular response to shear stress
(Fig. 4C). Since the FGR fetoplacental vasculature had
displayed minimal flow-mediated vasodilatation under
basal perfusion, L-NNA had little effect in reducing it
further (Fig. 4D).
Flow-mediated NO production by HPAECs is increased
in FGR
To further investigate NO production by the fetoplacental
endothelium in FGR, we turned our attention to
fetoplacental endothelial cells isolated from chorionic
plate arteries. The clinical characteristics of the patient
study groups that HPAECs were isolated from are
described in Table 1. HPAECs from normal (Fig. 5A) and
FGR pregnancy (Fig. 5B) demonstrated NO generation
in a shear stress- and time-dependent manner. NO
production was greater in the FGR group compared to
normal cells (Fig. 5C; both exposed to 48h of shear stress
at 20 dyn cm–2). NO generation by FGR HPAECs was
significantly inhibited by L-NNA (100 μM) (Fig. 5D).
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Figure 1. Correlations between in vivo pulsatility and resistance indices (PI and RI) in the umbilical
artery and ex vivo perfused cotyledon resistance
Fetal-side inflow hydrostatic pressure (FIHP), which is proportional to vascular resistance in the fetoplacental
circulation, was measured at a flow rate of 6 ml min−1 in normal (n = 10; A and B) and FGR placentas (n = 8,
as RI and PI data cannot be obtained from two cases with absent or reversed end-diastolic flow; C and D) and
correlated with clinical measures of both PI (A and C) and RI (B and D) in the umbilical artery obtained by Doppler
velocimetry, using the Pearson coefficient correlation.
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Expression and activation of eNOS in HPAECs are
increased in FGR
Total eNOS expression was significantly higher in
static cultured HPAECs isolated from FGR placentas
(Fig. 6A). There was also a trend (P = 0.065)
towards increased levels of activated eNOS, assessed
by Ser1177 phosphorylation in these cultures (data
not shown), suggested by phosphokinase array data,
which demonstrated a 10-fold increase in eNOS Ser1177
phosphorylation when comparing pooled lysates from
control and FGR HPAECs (4 cell lines pooled for
each group, data not shown). Inducible NO synthase
(iNOS) was also observed at significantly higher levels
in static cultured FGR HPAECs compared to normal cells
(P < 0.05) (Fig. 6B). Exposure of normal HPAECs to
unidirectional laminar shear stress (20 dyn cm–2) did not
elevate expression of eNOS (Fig. 6C), but did significantly
increase its activation (P < 0.05) (Fig. 6D).
Discussion
In this study we provide data which support the
concept that small resistance vessels and stem villi
vessels of the fetoplacental circulation, as studied in
ex vivo placental perfusion, are the loci that determine
umbilicoplacental resistance, as measured via umbilical
artery Doppler velocimetry in the clinic. In addition, we
demonstrate that vascular resistance in the fetoplacental
circulation measured ex vivo is significantly higher in
FGR than in normal pregnancies. The key finding from
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Figure 2. Vascular resistance in placentas from normal and fetal growth restricted (FGR) pregnancies
A, ex vivo dually perfused placental lobules were subjected to staged (7 min) incremental increases in fetal-side
perfusate flow and fetal-side inflow hydrostatic pressure (FIHP) measured as an indication of vascular resistance.
Traces are representative of FIHP in normal (Aa) and FGR (Ab) placentas. B, mean resistance values in placental
lobules from normal (n = 10; open squares) and FGR (n = 10; filled squares) pregnancies were obtained for all
flow rates during steady-state, 6–7 min following alterations in flow. Two-way ANOVA: P < 0.0001; Bonferonni
test: ∗P < 0.05, ∗∗P < 0.01. C, flow-mediated vasodilatation (FMVD) was measured as the percentage decrease in
FIHP, from peak FIHP to the new steady state following an elevation in flow, in normal (open bar) and fetal growth
restricted (filled bar) placentas. Data show means ± SEM; 2-way ANOVA: P < 0.001; Bonferonni test: ∗P < 0.05,
∗∗P < 0.01.
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the study, however, is the inability of FGR placentas
to elicit vasodilatation in response to increases in
flow, a response present in the normal fetoplacental
circulation. We are not aware of any previous report
demonstrating FMVD in the fetoplacental vasculature
of the perfused organ, nor previous data demonstrating
that it is severely perturbed in human FGR. However,
NO is involved in flow-induced dilatation of isolated
human small fetoplacental arteries (Learmont & Poston,
1996). Moreover in normal pregnancy, a direct negative
correlation between FMVD and vascular resistance, as
measured by umbilical artery Doppler velocimetry, was
observed; placentas less able to adapt to increases in
flow exhibited elevated resistance. Since flow- or shear
stress-mediated vasodilatation represents a functional
response predominantly orchestrated by the vascular end-
othelium, these results are consistent with our hypothesis
that in FGR, the fetoplacental circulation exhibits end-
othelial dysfunction. This was supported by in vitro shear
stress studies on HPAECs, which revealed altered NO
signalling in cells from FGR pregnancies.
The remarkable correlation between umbilical artery
resistance measurements determined in normal pre-
gnancies in vivo and ex vivo perfusion pressure in the
same placenta provides direct evidence that umbilical
artery velocimetry values reflect vascular resistance in the
fetoplacental circulation. Importantly, this correlation did
not hold for the FGR group, and although generally the
vascular resistance measured both in vivo and ex vivo was
higher in this group, therewasnoclear correlationbetween
the two measurements. Placental flow dysregulation in
FGR is likely to be mainly caused by architectural
vessel malformation and/or endothelial dysregulation.
Alteration to placental capillary angiogenesis (Kingdom
et al. 2000) and a general reduction in the luminal volume
density of vasculature at the periphery of FGR placentas
(Junaid et al. 2014) are likely to contribute to enhanced
vascular resistance in some cases. This scenario suggests
20
15
10
5
0
20
15
10
5
0
20
15
10
5
0
20
15
10
5
0
0.0
F
M
V
D
 (
%
 F
IH
P
 r
ed
uc
tio
n)
F
M
V
D
 (
%
 F
IH
P
 r
ed
uc
tio
n)
F
M
V
D
 (
%
 F
IH
P
 r
ed
uc
tio
n)
F
M
V
D
 (
%
 F
IH
P
 r
ed
uc
tio
n)
0.5 1.0 1.5 2.0
0.0 0.5 1.0 1.5 2.0
0.0 0.2 0.4 0.80.6 1.0
0.0 0.2 0.4 0.80.6 1.0
RI
RI
PI
PI
P < 0.05
r2 = 0.5258
P < 0.01
r2 = 0.6186
P = NS
r2 = 0.0127
P = NS
r2 = 0.0239
A B
C D
Figure 3. Correlations between in vivo pulsatility and resistance indices (PI and RI) and flow-mediated
vasodilatation (FMVD)
FMVD, assessed as the percentage decrease in fetal-inflow hydrostatic pressure (FIHP) from peak FIHP to the new
steady state following an elevation in flow, was measured in normal (n = 10; A and B) and FGR placentas (n = 8,
as RI and PI data cannot be obtained from two cases with absent or reversed end-diastolic flow; C and D) during
ex vivo dual perfusions at a flow rate of 6 ml min−1 and correlated with the umbilical artery Doppler pulsatility
index (PI) (A and C) and resistance index (RI) (B and D) using the Pearson correlation coefficient. Two FGR cases
had absent end-diastolic flow in the umbilical artery, preventing their inclusion.
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that the endothelia of the architecturally constrained
vessels in FGR are not dysfunctional. However, the fact
that resistance in vivo and ex vivo did not correlate well
in the FGR placentas in this study, i.e. that some FGR
cases showing high umbilical artery resistance found in
the clinic did not manifest as a high ex vivo resistance
during perfusion, does suggest that factors other than
vessel malformation are involved and that an endothelial
response is dysregulated.We suggest the lack of correlation
is caused by the loss of ex vivo vasoreactivity in the FGR
group, as the endocrine milieu with a pro-constriction
bias becomes washed out during blood-free perfusion.
The significant increase in vascular resistance, which
was observed in our FGR perfusion experiments, is in
contrast to a previous study by Luria et al. (2012), which
demonstrated nodifference in the basal perfusion pressure
in FGR and normal placentas during ex vivo perfusion.
Discrepancy between the studies is likely to be due to
the low fetal-side inflow rate used (6 ml min−1) by
Luria et al. and FGR being defined as below the 10th
centile of growth. In the current study, resistance was
only significantly elevated at flow rates above 6 ml min−1,
which are more akin to physiological flow rates when the
ex vivo perfused tissue mass is standardised to in vivo
values of blood flow to the whole placenta in the third
trimester. This calculation was derived from an estimate
that the normal placenta receives on average 21% of right
ventricular output across the third trimester of pregnancy,
equating to ca 180–250 ml min−1 for the whole placental
mass (Kiserud et al. 2006). Hence, relating to the ex vivo
perfusion of 35 g of term normal placental tissue, one
might expect this mass to have experienced an average
of 12 ml min−1 of in vivo blood flow after 32 weeks of
gestation, although this value is likely to be reduced by
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Figure 4. Contribution of nitric oxide (NO) to fetoplacental resistance and flow-mediated vasodilatation
(FMVD)
Ex vivo dual perfusion of human placental lobules was performed following the inhibition of nitric oxide synthase.
Vascular resistance was measured in normal placentas (n = 10; open symbols; A) or fetal growth restricted (FGR)
placentas (n = 10; filled symbols; B) at increasing flow rates in the presence (circles) or absence (squares) of L-NNA
(100 μM). FMVD, taken as the percentage decrease in fetal-inflow hydrostatic pressure (FIHP) from the initial peak
to the new steady state following an elevation in flow, was measured in placentas from control (n = 10; C) and
FGR pregnancies (n = 10; D) in the presence (filled bars) and absence (open bars) of L-NNA (100 μM). L-NNA had a
significant effect on FIHP in normal and FGR perfused placental lobules (P < 0.001 and P < 0.0001, respectively).
The flow-mediated vasodilatory effect was significantly reduced by L-NNA in normal and FGR perfused lobules
(P < 0.0001 and P < 0.05, respectively). All data are presented as means ± SEM (ANOVA with Bonferroni post
hoc test: ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
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approximately 25% in the FGRgroup (Kiserud et al. 2006).
In a further difference to the Luria study, we defined FGR
as the fifth centile and below to limit the inclusion of
constitutively small fetuses, which are likely to display the
normal ‘reactive’ phenotype.
In our cohort of 10 FGR placentas that was sufficiently
intact for ex vivo organ perfusion, five had poor umbilical
artery Doppler waveforms. However, as a whole, the FGR
placentas (i.e. those with poor and normal umbilical
artery waveforms) had higher vascular resistance ex vivo
compared to the normal group. Umbilical artery Doppler
indices indicate that fetoplacental vascular resistance falls
with gestational age in normal pregnancy. As 60% of
the perfused placentas from FGR pregnancies were below
the minimum gestational age of the normal group, it is
possible that gestational age contributed to the elevated
vascular resistance observed in FGR. For the minimal
gestational age case in the normal group (38 weeks +
4 days), the Doppler RI is estimated at 0.60, based on a
linear regression plot of 1663 pregnancies between 24 and
42 weeks (Kurmanavicius et al. 1997). For the six FGR
cases falling below this gestational age, a median gestation
of 36weeks+ 1day equates to an expectednormalRI value
of 0.62. Therefore, a higher resistance to flow in the FGR
group compared to normal of just over 3% is expected as
a consequence of the gestational age difference. However,
the actual difference in basal perfusion pressure was 70%
at a flow of 10 and 12 ml min−1 (Fig. 2), indicating that
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Figure 5. Shear stress-mediated NO production in HPAECs from control and growth restricted pre-
gnancies
HPAECs isolated from control (A; n = 6) and FGR (B; n = 6) placentas were cultured under static or shear
stress conditions for 48 h and nitrite concentration measured in flow conditioned media as an indication of nitric
oxide production. There was a significant effect of time on nitrite formation in both groups; and at each time
point, shear stress increased nitrite production compared to static culture (2-way ANOVA: P < 0.0001, both
groups; Bonferonni multiple comparison test: ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001, respectively). Nitrite,
as a proportionate measure to NO, generated by FGR HPAECs (filled bars) was significantly greater than control
HPAECs (open bars) following 48 h exposure to increasing shear stress conditions (C; 2-way ANOVA: P < 0.05;
Bonferroni multiple comparison test: ∗∗P < 0.01). The production of nitrite, proportionate to NO release, by normal
and FGR HPAECs in response to 48 h shear stress (at 20 dyn cm–2) was measured in the presence and absence of
L-NNA (100 μM) (D); L-NNA caused a significant reduction only in the FGR group (Sidak’s multiple comparison test:
∗∗∗∗P < 0.0001).
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the elevated resistance in FGR is caused predominantly by
abnormal vascular functionassociatedwith this pregnancy
complication.
Correlations between FMVD in vitro and resistance
values measured in vivo demonstrate that placentas
from normal pregnancy which exhibit low resistance to
flow in the fetoplacental circulation exhibit the largest
compensatory responses when flow is increased. FMVD
is largely regulated by endothelial cells and is often used
as a measure of endothelial function (Poredos & Jezovnik,
2013). These data therefore provide indirect evidence of
endothelial dysfunction in FGR, resulting in perturbed
FMVD and increased vascular resistance. Vasodilatation
in response to changes in blood flow is not only significant
as a measure of endothelial function, but also physio-
logically relevant; blood volume and subsequently flow
are increased as gestationprogresses (Reynolds et al.2006).
Furthermore, the spatial nature of fetoplacental bloodflow
may alter acutely during fetal- and maternal-side ‘blood
flow matching’ – a dynamic occurrence, where versatility
in the spatiotemporal fetoplacental blood flow is suggested
to be a key element in the optimisation of placental
oxygen transfer (Carter, 1989). In this regard, FMVD in
fetoplacental vesselsmaybe an important secondary event,
following the initial agonist-evokedvasodilatory signalling
mechanism that redefines the fetoplacental villous blood
flow pattern during ‘blood flow matching’.
NO is arguably the most important vasodilator in
the fetoplacental circulation, and plays a crucial role in
facilitating the pregnancy-induced vascular adaptations
involved in maintaining low resistance (Myatt, 1992;
Myatt et al. 1992; Magness et al. 1997; Sladek et al.
1997). Evidence in support of this includes a significant
increase inNOproductionby the fetoplacental vasculature
during pregnancy and an elevation in the expression of
secondary messenger cyclic guanosine monophosphate
(cGMP) (Magness et al. 1997; Sladek et al. 1997).
Moreover, prolonged inhibition of NO generation in
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Figure 6. eNOS expression and
activation in control and FGR HPAECs
Western blots were performed on lysates
from normal and FGR HPAECs cultured
under static conditions (passage 5–8) to
detect eNOS (n = 3 and 4, respectively; A),
activated and iNOS (n = 7, both groups; B).
(Data represented as means ± SEM;
∗P < 0.05, unpaired t test.) eNOS (n = 7,
both groups; C) and activated
P-Ser1177-eNOS expression (n = 7, both
groups; D) were compared in normal
HPAECs following static and shear stress
conditions (∗P < 0.05, paired t test).
Expression was normalised to β-actin
expression and is shown as means ± SEM.
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animal models results in FGR (Baylis et al. 1992; Sladek
et al. 1997), primarily through altered fetoplacental
adaptations (Kulandavelu et al. 2012). Given the pivotal
role of NO in regulating placental vascular tone and
considering its well characterised role in FMVD in other
vascular beds (Stoner et al. 2012), we investigated whether
NO production was reduced in FGR, which could explain
the lack of FMVD and increased vascular resistance. Inter-
estingly our data suggest that the heightened resistance
to flow in this pathology is not due to an inability of
the endothelium to generate NO; indeed collectively, our
organ perfusion and placental endothelial cell shear stress
studies show an up-regulation of NOS/eNOS activity in
this circulation; and remarkably in FGR HPAEC cultures,
up-regulation of expression and activity was sustained
through several passages and until the endothelial cells
stopped dividing. These data suggest that the in vivo FGR
environment can permanently change the endothelial cell
phenotype. In this study, eNOS activation was assessed
by phosphorylation of S1177; however, several other
phosphorylation sites are associated with eNOS activity.
Phosphorylation of the S633 amino acid residue results
in enhanced NO production, whereas phosphorylation of
T495 inhibits eNOS activity. While shear stress stimulates
phosphorylation of both S1177 and S633 residues, it
does not dephosphorylate T495 (Boo et al. 2002). Here
we report a higher S1177 phosphorylation in the FGR
HPAECs, complementing the finding of comparatively
higher nitrite levels in the flow conditioned medium of
this group. Ideally, other phosphorylation sites would
be investigated had there been a sufficient quantity of
recovered cell lysate.
Sustained iNOS up-regulation is normally associated
with chronic conditions of vascular inflammation (Peng
et al. 1998). The continued expression of iNOS in
endothelial cells from FGR placentas suggests such
inflammation is a feature of this condition, consistent with
recent data on placentas associated with poor pregnancy
outcome (Girard et al. 2014). Endothelial inflammation
may also contribute to the general elevated resistance
to flow in ex vivo perfused placental lobules from FGR
pregnancy, through the loss of a smoothmorphology at the
luminal facing membrane, thus promoting turbulent flow
(Leach& Firth, 1995). In some animal studies, nitric oxide
bioavailability has been shown to be altered during labour,
which could have a significant impact on our findings
given the differences in mode of delivery between women
having normal pregnancy and FGR. In human studies,
however, nitric oxide synthase activity is not altered
(Thomson et al. 1997), and eNOS and iNOS transcription
in the placenta is unchanged (Cindrova-Davies et al.
2013). Moreover, there is some evidence to suggest that
labour does not affect vascular reactivity of chorionic plate
arteries (Abad et al. 2003; Mills et al. 2007). Collectively,
these data indicate that the alterations in NO that we
present are a direct result of FGR and not due to the
difference in mode of labour between the two groups.
Our work is supportive of other evidence that shows
up-regulation of eNOS activity in FGR (Rutherford et al.
1995;Lyall et al.1996;Myatt et al.1997) inaddition tomore
recent studies that have demonstrated increased levels of
nitrite in umbilical cord blood (Pisaneschi et al. 2012).
However, the role of NO in FGR is controversial and
there are numerous studies demonstrating reduced NO
generation and reduced NO-dependent vasodilatation in
FGR (Casanello & Sobrevia, 2002; Casanello et al. 2009;
Krause et al. 2012, 2013). Studies by Krause and colleagues
have shown reduced insulin-evoked NO vasodilatation in
intra-uterine growth restricted human umbilical arteries
(IUGR; 2nd–10th IBR) using wire myography (Krause
et al. 2012). Enhanced L-arginase expression in human
umbilical arterial endothelial cells isolated from IUGR
placentas was also noted and the authors concluded that
increased L-arginase expression reduced the availability of
L-arginine to eNOS, which reduced NO production and
compromised vasodilatation (Krause et al. 2012, 2013).
There are various differences between the study of Krause
and ours which may account for the contrasting results.
Firstly, the loci and cell types studied: we focused on
the fetoplacental vasculature, which determines vascular
resistance, rather than the umbilical vessels. Secondly, our
study also included physiological levels of eNOS substrate
L-arginine in our buffers, which there is no mention of in
the Krause studies. Thirdly, the definition of FGR in the
studies also varies. It is important to note that despite the
increased NO release in FGR placentas found here, these
dilator levels failed to compensate for the high resistance
found and the causative factor of increased vascular tone
remains elusive.
Dysregulation of fetoplacental function through the
imbalanced production of other vasoactive substances
needs to be evaluated in future work. For example,
angiotensin II (A-II), an acute vasoconstrictor of the
human fetoplacental vasculature (Glance et al. 1986;
Brownbill & Sibley, 2006), is reported to be elevated
in the fetal circulation of human FGR pregnancies
(Kingdom et al. 1993). Furthermore, A-II has the potential
to up-regulate eNOS expression and activity in ovine
fetoplacental arterial endothelial cells (Zheng et al. 2005).
Hence, it would be interesting to determine any potential
A-II effects on eNOS expression and assess possible
changes in NO output under shear stress conditions in
the human HPAEC cells.
In summary this study identified small blood vessels
within the fetoplacental circulation as the primary loci
which define vascular resistance in the umbilico-placental
circulation in normal pregnancy. It is important to
note that the ex vivo perfusion used in this study is
largely exclusive of conduit arteries that may function
differently to smaller microvessels. In FGR, these
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small blood vessels within the fetoplacental vasculature
exhibit dysfunction resulting in reduced FMVD and
increased vascular resistance. NO production is elevated
in FGR, and goes some way to compensating for the
increased resistance to flow, but cannot completely rescue
levels back to within the normal range. It is unclear
whether the NO compensation mechanism is at full
capacity in FGR, or whether therapeutic interventions
with the supplementation of L-arginine, the addition
of the eNOS co-factor tetrahydrobiopterin, L-arginase
inhibition, or sildenafil treatment to maintain cGMP
levels in vascular smoothmuscle would provide additional
augmentation of this signalling pathway in humans.
Further work is therefore required to determine whether
the over-expressionofNOcanbe therapeutically exploited
orwhether other signalling pathways should be considered
as therapeutic targets to induce fetoplacental vaso-
dilatation and reduce vascular resistance to rescue fetal
growth. Elucidation of the constricting factor(s) which
lead to elevated vascular resistance in FGR may also lead
to the development of novel therapeutic strategies.
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Translational perspective
Understanding the mechanisms that lead to a fetus not meeting its predetermined genetic growth
potential is a key step in identifying therapeutic targets and safemedicines for use in these pregnancies.
There is considerable controversy in the literature regarding the up- or down-regulation of NO in
pregnancies complicated by fetal growth restriction (FGR), since (i) some studies, such as nitrite
measurement in fetal plasma conditioned by the whole fetal circulation, have used an assay prone to
biochemical noise from Hb, and (ii) experimental designs have been used which are not reflective
of resistance in the fetoplacental vascular bed, or are not inclusive of an endothelial response of
placental origin, under shear stress conditions. To this end, our multi-model approach has overcome
these caveats. We report an upregulation in NO synthesis, which represents a failed compensatory
response to high fetoplacental vascular resistance in FGR. Furthermore, the ex vivo dual placenta
model provides reliable resistance data for the fetoplacental microcirculation, tightly correlated to
umbilical arterial in vivo resistance in the clinic, in normal pregnancy. Therefore our data support
the use of the ex vivo systems, as described, as a useful testing platform for potential therapeutics to
be used in the treatment of FGR. Our data also provide further support for targeting NO generating
systems in the development of such therapies.
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